Pulmonary Tuberculosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Pulmonary Tuberculosis. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Pulmonary Tuberculosis receives a directional score of 56/100, combining unmet need (68/100), competitive intensity (96/100) and market attractiveness (80/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

MYCOBACTERIUM infections of the lung.

The reproducible record is Patsnap disease ID 764eee63555942f1bb171f1b8c1e71ea and MeSH identifier D014397. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Prevalence of pulmonary tuberculosis among the tribal populations in India Prevalence of pulmonary tuberculosis amongthe tribal populations in India

This is the first study of its kind that reports the prevalence of pulmonary TB among the tribal populations across India. The study gains importance as the only reference to the overall prev- alence of TB among the tribal populations till date was based on a meta-analysis by Thomas et al., 2015 [13] that reported a pooled PTB prevalence estimate of 703 (95%CI: 386–1011) per 100000 with a high degree of variation indicated by the wide confidence intervals. The results of the current study report an overall prevalence of PTB as 432 per 100000 (95% CI: 373–491), with a much smaller confidence interval. The high estimate in the meta-analysis could have been due to the fact that 5 of the 7 studies, were from Madhya Pradesh in Central India [7, 12, 14, 16, 22], and among them, 3 were on Sahariya tribes with the prevalence of PTB reported between of 387–1518 per 100,000 populations [7, 15, 16]. The bacteriologically positive PTB prevalence (432/100,000) among tribal populationss identified from our findings is higher compared with the PTB prevalence in the general Table 3. Multivariate analysis for the factors associated with the occurrence of pulmonary tuberculosis. aOR—Odds Ratio; aOR was estimated after adjusting for the covariates and cluster effects. https://doi-org.sutd.idm.oclc.org/10.1371/journal.pone.0251519.t003 populations based on the pooled estimate of 350 (95%CI: 261–439) per 100,000 [4]. While we have chosen to compare our findings with this estimate as the methods employed are similar, there are two more studies that have reported pooled estimates of 296 and 316 per 100,000 [3, 23]

Review source

Epidemiology evidence 2: Prevalence of Pulmonary Tuberculosis - A Baseline Survey In Central India Prevalence of Pulmonary Tuberculosis - A BaselineSurvey In Central India

after intensive tuberculosis control project and implementation of a national tuberculosis programme. Bull World Health Organ 82: 836–843. 15. Bhat J, Rao VG, Gopi PG, Yadav R, Selvakumar N (2009) Prevalence of Pulmonary tuberculosis amongst the tribal population of Madhya Pradesh, central India. Int J Epidemiol 38(4):1026–1032. 16. Rao VG, Gopi PG, Bhat J, Selvakumar N, Yadav R, et al. (2010) Pulmonary tuberculosis: a public health problem amongst Saharia, a primitive tribe of Madhya Pradesh, central India. Int J Infect Dis 14: e713-e716. 17. Rao VG, Bhat J, Yadav R, Gopi PG, Selvakumar N (2010) Pulmonary Tuberculosis among Bharia - a primitive tribe of Madhya Pradesh. Int J Tuberc Lung Dis 14(3):368–370. 18. Yadav R, Rao VG, Bhat J, Gopi PG, Selvakumar N (2010) Tuberculosis prevalence among Baiga primitive tribe of Madhya Pradesh. Indian J Tuberc 57(2):114–116. 19. World Health Organization (2010) Global tuberculosis control: WHO report 2010. WHO/HTM/TB/2010.7. 20. Pamra SP, Goyal SS, Mathur GP (1973) Changes in prevalence and incidence of pulmonary tuberculosis in recent years. Indian J Tuberc 20. 21. Gothi GD, Chakraborty AK, Nair SS, Ganapathy KT, Banerjee GC (1979) Prevalence of tuberculosis in a South Indian district-twelve years after initial survey. Indian J Tuberc 26: 121. 22. International Institute for Population Sciences (IIPS) and Macro International (2005–2006) National Family Health Survey (NFHS-3), India: Volume I. Mumbai: IIPS, 2007. 23. Tupasi TE, Radhakrishna S, Rivera AB, Pascual ML, Quelapio MI, et al. (1999) The 1997 Nationwide Tuberculosis Prevalence

Review source

Epidemiology evidence 3: Global tuberculosis report 2022 2. Global TB commitments, strategy and targets

TB determinants (Box 4). These include average income (measured as gross domestic product [GDP] per capita) and the prevalence of undernourishment, both of which are closely associated with TB incidence (Fig. 20). Wors- ening trends in these two indicators, and others such as levels of poverty, could increase the probability of developing TB disease among people already infected with M. tuberculosis and their mortality rate. Declines in income may also affect health care seeking behaviour when people become unwell, making delays in TB diag- nosis and treatment more likely. Estimation of TB disease burden New direct measurements needed Estimating TB disease burden during the COVID-19 pandemic is difficult and currently relies on country- and region-specific dynamic models for many LMICs (Box 4). This is in contrast to the methods used for the period 2000–2019.1 These included use of results from population-based surveys of the prevalence of TB dis- ease that were implemented between 2000 and 2019 to inform estimates of TB incidence in 29 countries that accounted for about two-thirds of global TB incidence; and use of data from national VR systems or mortality surveys for the period 2000–2019 to inform estimates of the number of TB deaths in 123 countries that account- ed for about 60% of the global number of TB deaths among HIV-negative people. For this report, there were only two high TB burden or global TB watchlist countries for which data on the number of TB deaths in the period 2020–2021 were available from national VR systems and shared with the WHO Global TB Programme

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Pulmonary Tuberculosis, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Pulmonary Tuberculosis thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: ALK5

Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis (PubMed:33914044). The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.

The mechanism anchor is TGFBR1, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 1093 registered studies.

• ChiCTR2600130528 — Study on the impact of rapid nucleic acid detection technology based on PCR-fluorescent probe method on the diagnosis and treatment of pulmonary tuberculosis.; Not yet recruiting; Not Applicable; sponsor The First Affiliated Hospital of the Hainan Medical College; enrollment not stated.
• NCT07773610 — Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis (SYNERGY); Not yet recruiting; Phase 2; sponsor TASK Applied Science; enrollment 135.
• ChiCTR2600129766 — Association between Psychosocial Factors and Tuberculosis Complication Risk in Type 2 Diabetes Patients; Not yet recruiting; Not Applicable; sponsor Shenzhen Futian People's Hospital; enrollment 150.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate TGFBR1 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Pulmonary Tuberculosis merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Pulmonary Tuberculosis is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.